Early and late oral features of chronic graft-versus-host disease

Revista Brasileira de Hematologia e Hemoterapia

Volumn 36, Issue 1, 2014, Pages 43-49

  Gomes, Alessandra Oliveira Ferrari ^a   Torres, Sandra Regina ^a   Maiolino, Angelo ^a   Dos Santos, Cesar Werneck Noce ^a   Silva Junior, Arley ^a,b   Correa, Maria Elvira Pizzigatti ^c   Moreira, Maria Cláudia Rodrigues ^d   Gonçalves, Lucio de Souza ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b FLUMINENSE FEDERAL UNIVERSITY   (Brazil)

^c UNIVERSITY OF CAMPINAS   (Brazil)

^d INSTITUTO NACIONAL DE CÂNCER   (Brazil)

Author keywords

Chronic disease; Diagnosis, oral; Graft versus host disease; Hematopoietic stem cell transplantation

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; FLUDARABINE;

ADULT; ARTICLE; ATROPHY; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL FEATURE; CROSS-SECTIONAL STUDY; ERYTHEMA; FEMALE; FLOW RATE; GINGIVA HYPERPLASIA; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HYPOSALIVATION; LICHENOID; MAJOR CLINICAL STUDY; MALE; MOUTH DISEASE; MOUTH LESION; MOUTH OPENING RANGE; MOUTH ULCER; MUCOCELE; PAIN; SALIVARY GLAND FUNCTION; VISUAL ANALOG SCALE; XEROSTOMIA;

EID: 84897820314     PISSN: 15168484     EISSN: None     Source Type: Journal    
DOI: 10.5581/1516-8484.20140012     Document Type: Article

References (30)

1. Nicolatou-Galitis O, Kitra V, Van Vliet-Constantinidou C, Peristeri J, Goussetis E, Petropoulos D, et al. The oral manifestations of chronic graft-versus-host disease (cGVHD) in paediatric allogeneic bone marrow transplant recipients. J Oral Pathol Med. 2001;30(3):148-53.
2. Schubert MM, Correa ME. Oral graft-versus-host disease. Dent Clin North Am. 2008;52(1):79-109.
3. Noce CW, Gomes A, Copello A, Barbosa RD, Sant'anna S, Moreira MC, et al. Oral involvement of chronic graft-versus-host disease in hematopoietic stem cell transplant recipients. Gen Dent. 2011;59(6):458-62.
4. Boer CC, Correa ME, Miranda EC, de Souza CA. Taste disorders and oral evaluation in patients undergoing allogeneic hematopoietic SCT. Bone Marrow Transplant. 2010;45(4):705-11.
5. Imanguli MM, Pavletic SZ, Guadagnini JP, Brahim JS, Atkinson JC. Chronic graft-versus-host disease of oral mucosa: review of available therapies. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006;101(2):175-83.
6. Flowers ME, Parker PM, Johnston LJ, Matos AV, Storer B, Bensinger WI, et al. Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: long-term follow-up of a randomized trial. Blood. 2002;100(2):415-9.
7. Lee SJ, Flowers ME. Recognizing and managing chronic graft-versus-host disease. Hematology Am Soc Hematol Educ Program. 2008:134-41.
8. Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005;11(12):945-56.
9. Woo SB, Lee SJ, Schubert MM. Graft-vs.-host disease. Crit Rev Oral Biol Med. 1997;8(2):201-16.
10. Torres SR, Peixoto CB, Caldas DM, Silva EB, Akiti T, Nucci M, et al. Relationship between salivary flow rates and Candida counts in subjects with xerostomia. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2002;93(2):149-54.
11. Jensen SB, Pedersen AM, Reibel J, Nauntofte B. Xerostomia and hypofunction of the salivary glands in cancer therapy. Support Care Cancer. 2003;11(4):207-25.
12. Imanguli MM, Atkinson JC, Mitchell SA, Avila DN, Bishop RJ, Cowen EW, et al. Salivary gland involvement in chronic graft-versus-host disease: prevalence, clinical significance, and recommendations for evaluation. Biol Blood Marrow Transplant. 2010;16(10):1362-9.
13. Pai S, Ghezzi EM, Ship JA. Development of a Visual Analogue Scale questionnaire for subjective assessment of salivary dysfunction. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2001;91(3):311-6.
14. Fall-Dickson JM, Mitchell SA, Marden S, Ramsay ES, Guadagnini JP, Wu T, St John L, Pavletic SZ; National Institutes of Health Chronic Graft-versus-Host Disease Study Group. Oral symptom intensity, health-related quality of life, and correlative salivary cytokines in adult survivors of hematopoietic stem cell transplantation with oral chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2010;16(7):948-56.
15. Márton K, Madléna M, Bánóczy J, Varga G, Fejérdy P, Sreebny LM, et al. Unstimulated whole saliva flow rate in relation to sicca symptoms in Hungary. Oral Dis. 2008;14(5):472-7.
16. Nagler R, Barness-Hadar L, Lieba M, Nagler A. Salivary antioxidant capacity in graft-versus-host disease. Cancer Invest. 2006;24(3):269-77.
17. Dijkstra PU, Huisman PM, Roodenburg JL. Criteria for trismus in head and neck oncology. Int J Oral Maxillofac Surg. 2006;35(4):337-42.
18. Allen JL, Fore MS, Wooten J, Roehrs PA, Bhuiya NS, Hoffert T, et al. B cells from patients with chronic GVHD are activated and primed for survival via BAFF-mediated pathways. Blood. 2012;120(12):2529-36.
19. Arora M, Klein JP, Weisdorf DJ, Hassebroek A, Flowers ME, Cutler CS, et al. Chronic GVHD risk score: a Center for International Blood and Marrow Transplant Research analysis. Blood. 2011;117(24):6714-20. Comment in: Blood. 2011;117(24):6408-9.
20. Treister NS, Cook EF Jr, Antin J, Lee SJ, Soiffer R, Woo SB. Clinical evaluation of oral chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2008;14(1):110-5.
21. Nagler R, Marmary Y, Krausz Y, Chisin R, Markitziu A, Nagler A. Major salivary gland dysfunction in human acute and chronic graft-versus-host disease (GVHD). Bone Marrow Transplant. 1996;17(2):219-24.
22. Nagler RM, Nagler A. Salivary gland involvement in graft versus-host disease: the underlying mechanism and implicated treatment. Isr Med Assoc J. 2004;6(3):167-72.
23. Ship JA, Pillemer SR, Baum BJ. Xerostomia and the geriatric patient. J Am Geriatr Soc. 2002;50(3):535-43.
24. Torres SR, Lotti RS, Peixoto CB, Graça PA, Lima ME, Pina CC, et al. Efficacy of a questionnaire about xerostomia for the detection of hyposalivation. Rev Assoc Paul Cirurg Dent. 2002;56(3):227-31.
25. Skert C, Patriarca F, Sperotto A, Cerno M, Filì C, Zaja F, et al. Sclerodermatous chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: incidence, predictors and outcome. Haematologica. 2006;91(2):258-61.
26. Peñas PF, Jones-Caballero M, Aragüés M, Fernández-Herrera J, Fraga J, García-Díez A. Sclerodermatous graft-vs-host disease: clinical and pathological study of 17 patients. Arch Dermatol. 2002;138(7):924-34.
27. Tamagawa R, Takenaka H, Katoh N, Shimazaki C, Bamba H, Kishimoto S. Sclerodermatous chronic graft-versus-host disease presenting with dysphagia. Eur J Dermatol. 2006;16(1):92-3. Comment on: Eur J Dermatol. 2003;13(2):171-6.
28. Pedrazas CH, Azevedo MN, Torres SR. Oral events related to low-dose methotrexate in rheumatoid arthritis patients. Braz Oral Res. 2010;24(3):368-73.
29. Jean SM, Sharma P, Taylor D, Mook D. Cyclosporine induced gingival overgrowth in New Zealand White rabbits (Oryctolagus cuniculus). Comp Med. 2009;59(4):357-62.
30. Sreebny L. Saliva salivary gland hypofunction (SGH). FDI Working Group 10. J Dent Assoc S Afr. 1992;47(11):498-501.